Spotlight on Oncology

Credits: 0.5 CME
Podium to Practice™: Updates in the Treatment of DLBCL – From Chemotherapy to Novel Targeted Therapies
Justin Kline, MD
University of Nebraska Medical Center

Podium to Practice™: Updates in the Treatment of DLBCL – From Chemotherapy to Novel Targeted Therapies

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: November 12, 2021
Expires: November 12, 2022
30 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with DLBCL.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Compare and contrast various chemotherapy treatment regimens for the frontline treatment of patients with DLBCL
  • Assess the safety and efficacy of clinical data regarding novel targeted therapeutic approaches for patients with relapsed/refractory DLBCL
  • Identify strategies for improving patient outcomes, including optimal selection and sequencing of therapy, as well as adverse event management approaches

Activity Description

Podium to Practice™ is an exclusive accredited continuing education activity featuring two diffuse large B-cell lymphoma experts as they provide expert summary and guidance on the optimal use of current and emerging therapies and interpretation of data presented during the 2021 ASCO, EHA, and ICML Annual Meetings.

Statement of Educational Need

Whereas approximately 60% of patients with DLBCL are cured with standard chemoimmunotherapy, 20% are refractory to initial treatment, and another 20% will relapse and potentially die of the disease. Patients progressing through or relapsing after their treatment have a poor prognosis. Several targeted agents have proven effective, but the majority do not produce durable responses, requiring development in combination with other targeted or conventional therapies. Therefore, novel agents for patients with DLBCL have the greatest potential for improving outcomes in these relapsed/refractory patients.

Moderator

Justin Kline, MD
Director, Lymphoma Program
Associate Professor of Medicine
University of Chicago Medicine
Chicago, Illinois

Faculty

Laurie Sehn, MD
Clinical Assistant Professor, Division of Medical Oncology
The University of British Columbia
Vancouver, British Columbia

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Justin Kline, MD
Consultant Fees: Merck, Verastem, MorphoSys, Gilead, Karyopharm
Research Support: Merck, Verastem
Speakers Bureau: Kite/Gilead

Laurie Sehn, MD
Consultant Fees: AbbVie, AstraZeneca, Celgene, Gilead/Kite, Incyte, Janssen, Merck, Roche Genentech, Teva, Sandoz, Seattle Genetics

Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Chloe Dunnam; Dru Dace, PhD; Kraig Steubing

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from Merck Sharp & Dohme Corp and Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: November 12, 2021
Expires: November 12, 2022
30 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with DLBCL.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Compare and contrast various chemotherapy treatment regimens for the frontline treatment of patients with DLBCL
  • Assess the safety and efficacy of clinical data regarding novel targeted therapeutic approaches for patients with relapsed/refractory DLBCL
  • Identify strategies for improving patient outcomes, including optimal selection and sequencing of therapy, as well as adverse event management approaches

Activity Description

Podium to Practice™ is an exclusive accredited continuing education activity featuring two diffuse large B-cell lymphoma experts as they provide expert summary and guidance on the optimal use of current and emerging therapies and interpretation of data presented during the 2021 ASCO, EHA, and ICML Annual Meetings.

Statement of Educational Need

Whereas approximately 60% of patients with DLBCL are cured with standard chemoimmunotherapy, 20% are refractory to initial treatment, and another 20% will relapse and potentially die of the disease. Patients progressing through or relapsing after their treatment have a poor prognosis. Several targeted agents have proven effective, but the majority do not produce durable responses, requiring development in combination with other targeted or conventional therapies. Therefore, novel agents for patients with DLBCL have the greatest potential for improving outcomes in these relapsed/refractory patients.

Moderator

Justin Kline, MD
Director, Lymphoma Program
Associate Professor of Medicine
University of Chicago Medicine
Chicago, Illinois

Faculty

Laurie Sehn, MD
Clinical Assistant Professor, Division of Medical Oncology
The University of British Columbia
Vancouver, British Columbia

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Justin Kline, MD
Consultant Fees: Merck, Verastem, MorphoSys, Gilead, Karyopharm
Research Support: Merck, Verastem
Speakers Bureau: Kite/Gilead

Laurie Sehn, MD
Consultant Fees: AbbVie, AstraZeneca, Celgene, Gilead/Kite, Incyte, Janssen, Merck, Roche Genentech, Teva, Sandoz, Seattle Genetics

Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Chloe Dunnam; Dru Dace, PhD; Kraig Steubing

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from Merck Sharp & Dohme Corp and Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Oncology Presentations

0.25 CME / MOC
AKH Inc., Advancing Knowledge in Healthcare
Frontline Checkpoint Inhibitor Monotherapy in NSCLC

Frontline Checkpoint Inhibitor Monotherapy in NSCLC

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Points
Released: June 25, 2021
Expires: June 24, 2022
15 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with NSCLC.

Learning Objective

After completing this activity, the clinician should be able to:

  • Evaluate the survival advantage versus chemotherapy for current and emerging frontline checkpoint inhibitor monotherapies in advanced nondriver non-small cell lung cancer (NSCLC) with high PD-L1 expression

Activity Description

This learner-friendly 15-minute infographic activity is augmented by physician videos in an interactive approach to key safety and efficacy data for frontline pembrolizumab, atezolizumab, and cemiplimab monotherapies in advanced NSCLC.

Chair

Ahmet Sezer, MD
Professor, Medical Oncology
Başkent University
Adana, Turkey

Faculty

Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT


Brian Henick, MD
Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY


Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Ahmet Sezer, MD, has no financial relationships to disclose.

Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consulting Fees); AstraZeneca, Boehringer Ingelheim (Contracted Research).

Brian Henick, MD, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH CE Director of Accreditations, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Yael Waknine, Medical Director, has no financial relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
David Reilly, MSc, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 50% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Points
Released: June 25, 2021
Expires: June 24, 2022
15 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with NSCLC.

Learning Objective

After completing this activity, the clinician should be able to:

  • Evaluate the survival advantage versus chemotherapy for current and emerging frontline checkpoint inhibitor monotherapies in advanced nondriver non-small cell lung cancer (NSCLC) with high PD-L1 expression

Activity Description

This learner-friendly 15-minute infographic activity is augmented by physician videos in an interactive approach to key safety and efficacy data for frontline pembrolizumab, atezolizumab, and cemiplimab monotherapies in advanced NSCLC.

Chair

Ahmet Sezer, MD
Professor, Medical Oncology
Başkent University
Adana, Turkey

Faculty

Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT


Brian Henick, MD
Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY


Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Ahmet Sezer, MD, has no financial relationships to disclose.

Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consulting Fees); AstraZeneca, Boehringer Ingelheim (Contracted Research).

Brian Henick, MD, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH CE Director of Accreditations, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Yael Waknine, Medical Director, has no financial relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
David Reilly, MSc, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 50% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

0.25 CME / MOC
AKH Inc., Advancing Knowledge in Healthcare
Understanding Checkpoint Inhibitors in NSCLC

Understanding Checkpoint Inhibitors in NSCLC

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Points
Released: June 25, 2021
Expires: June 24, 2022
15 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with NSCLC.

Learning Objective

After completing this activity, the clinician should be able to:

  • Assess the relationship between checkpoint inhibitor mechanism of action and differential safety profile versus chemotherapy

Activity Description

This 15-minute infographic activity uses an interactive approach augmented by a whiteboard animation and clinician videos to delineate checkpoint inhibitor mechanisms of action, key safety points, and important aspects of patient counseling.

Chair

Ahmet Sezer, MD
Professor, Medical Oncology
Başkent University
Adana, Turkey

Faculty

Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT


Brian Henick, MD
Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY


Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Ahmet Sezer, MD, has no financial relationships to disclose.

Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consulting Fees); AstraZeneca, Boehringer Ingelheim (Contracted Research).

Brian Henick, MD, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH CE Director of Accreditations, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Yael Waknine, Medical Director, has no financial relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
David Reilly, MSc, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 50% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Points
Released: June 25, 2021
Expires: June 24, 2022
15 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with NSCLC.

Learning Objective

After completing this activity, the clinician should be able to:

  • Assess the relationship between checkpoint inhibitor mechanism of action and differential safety profile versus chemotherapy

Activity Description

This 15-minute infographic activity uses an interactive approach augmented by a whiteboard animation and clinician videos to delineate checkpoint inhibitor mechanisms of action, key safety points, and important aspects of patient counseling.

Chair

Ahmet Sezer, MD
Professor, Medical Oncology
Başkent University
Adana, Turkey

Faculty

Sarah B. Goldberg, MD, MPH
Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT


Brian Henick, MD
Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY


Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Ahmet Sezer, MD, has no financial relationships to disclose.

Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Janssen, Regeneron, Sanofi Genzyme, Takeda (Consulting Fees); AstraZeneca, Boehringer Ingelheim (Contracted Research).

Brian Henick, MD, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH CE Director of Accreditations, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Yael Waknine, Medical Director, has no financial relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
David Reilly, MSc, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 50% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

1.00 CME / CNE / CPE
Rush University Medical Center
Expanding Treatment Options for Advanced Hepatocellular Carcinoma: Understanding the Evolving Role of Systemic Therapies

Expanding Treatment Options for Advanced Hepatocellular Carcinoma: Understanding the Evolving Role of Systemic Therapies

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 22, 2021
Expires: June 21, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with hepatocellular carcinoma.

Learning Objectives

After completing this program, participants should be able to:

  1. Evaluate the latest clinical evidence regarding the safety and efficacy of TKIs and immune checkpoint inhibitors for the treatment of advanced HCC
  2. Identify and manage adverse events associated with the use of TKIs or immune checkpoint inhibitors to optimize patient outcomes
  3. Formulate individualized, evidence-based best-practice treatment plans for patients with advanced HCC, including consideration of prognostic factors, distinct target profiles, and safety considerations

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of hepatocellular carcinoma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

In recent years, numerous new targeted and immunotherapy agents have become available for the treatment of HCC, expanding the treatment options for the disease. However, the optimal use of these agents is still being defined based on emerging clinical data. Given the recent advances in available systemic and targeted therapies, an educational program addressing these topics is urgently needed so community clinicians are better equipped to formulate individualized treatment plans for their patients using the most recent best-practice clinical approaches.

Faculty

Ghasson K. Abou-Alfa, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Conflict of Interest Policy/Disclosure Statement

Dr. Abou-Alfa has consulted for:
Agios, AstraZeneca, Alnylam, Autem, Bayer, Beigene, Berry Genomics, Celgene, CytomX, Eisai, Eli Lilly, Exelixis, Flatiron, Genentech/Roche, Genoscience, Helio, Incyte, Ipsen, Legend Biotech, Loxo, Merck, MINA, QED, Redhill, Rafael, Silenseed, Sillajen, Sobi, Surface Oncology, Therabionics, Twoxar, Vector, Yiviva

Dr. Abou-Alfa has research grants from:
Arcus, Agios, AstraZeneca, Bayer BioNtech, BMS, Celgene, Flatiron, Genentech/Roche, Genoscience, Incyte, Polaris, Puma, QED, Sillajen, Yiviva

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Exelixis and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 22, 2021
Expires: June 21, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with hepatocellular carcinoma.

Learning Objectives

After completing this program, participants should be able to:

  1. Evaluate the latest clinical evidence regarding the safety and efficacy of TKIs and immune checkpoint inhibitors for the treatment of advanced HCC
  2. Identify and manage adverse events associated with the use of TKIs or immune checkpoint inhibitors to optimize patient outcomes
  3. Formulate individualized, evidence-based best-practice treatment plans for patients with advanced HCC, including consideration of prognostic factors, distinct target profiles, and safety considerations

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of hepatocellular carcinoma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

In recent years, numerous new targeted and immunotherapy agents have become available for the treatment of HCC, expanding the treatment options for the disease. However, the optimal use of these agents is still being defined based on emerging clinical data. Given the recent advances in available systemic and targeted therapies, an educational program addressing these topics is urgently needed so community clinicians are better equipped to formulate individualized treatment plans for their patients using the most recent best-practice clinical approaches.

Faculty

Ghasson K. Abou-Alfa, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Conflict of Interest Policy/Disclosure Statement

Dr. Abou-Alfa has consulted for:
Agios, AstraZeneca, Alnylam, Autem, Bayer, Beigene, Berry Genomics, Celgene, CytomX, Eisai, Eli Lilly, Exelixis, Flatiron, Genentech/Roche, Genoscience, Helio, Incyte, Ipsen, Legend Biotech, Loxo, Merck, MINA, QED, Redhill, Rafael, Silenseed, Sillajen, Sobi, Surface Oncology, Therabionics, Twoxar, Vector, Yiviva

Dr. Abou-Alfa has research grants from:
Arcus, Agios, AstraZeneca, Bayer BioNtech, BMS, Celgene, Flatiron, Genentech/Roche, Genoscience, Incyte, Polaris, Puma, QED, Sillajen, Yiviva

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Exelixis and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

0.75 CME / MOC / CNE
RMEI Medical Education, LLC
Changing Perspectives—Fine Tuning Treatment for the Relapsed Refractory Patient with Chronic Myeloid Leukemia

Changing Perspectives—Fine Tuning Treatment for the Relapsed Refractory Patient with Chronic Myeloid Leukemia

Start

Activity Details

Free CME/MOC/CNE
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Points
0.75 ANCC Contact Hours
Released: June 15, 2021
Expires: June 14, 2022
45 minutes to complete

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, hematologists, NPs, PAs, nurses, and other HCPs engaged in the care of patients with chronic myeloid leukemia (CML).

Learning Objectives

After completing this activity, the clinician should be able to:

  • Employ key data on tyrosine kinase inhibitors (TKIs) when treating and monitoring patients with relapsed or refractory CML
  • Select appropriate therapy for patients with CML refractory to 2nd generation agents
  • Integrate strategies to monitor and manage potential adverse effects, such as cardiotoxicity, that may result in cross-intolerance to TKIs in patients with CML

Activity Description

This Clinical Convergence™ activity addresses new developments in the treatment of relapsed/refractory CML with a focus on appropriate therapeutic decision making and monitoring in the second- and third-line setting. The program features a clinical case vignette to engage the learner and facilitate acquisition and integration of new skills and behaviors, as well as a patient encounter to provide unique perspectives on aspects of treatment selection, adherence, monitoring requirements, and adverse event management. A non-certified practice aid is included as a resource for provider-patient discussions on potential side effects.

Course Director

Jorge Cortes, MD
Director, Georgia Cancer Center
Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer
Augusta, GA

Faculty

Mahran Shoukier, MD
Hematology/Oncology Fellow
Section of Hematology/Oncology, Department of Medicine
Georgia Cancer Center at Augusta University
Augusta, GA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Jorge Cortes, MD, has affiliations with Novartis, Pfizer, Sun Pharmaceuticals, Takeda (Consultant and Grant Research Support).

Mahran Shoukier, MD, has no relevant financial relationship(s) with ineligible companies to disclose.

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planner, Sara Fagerlie, PhD, CHCP, has an affiliation with Adaptive Biotechnologies. All other RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.

No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC/CNE
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Points
0.75 ANCC Contact Hours
Released: June 15, 2021
Expires: June 14, 2022
45 minutes to complete

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncologists, hematologists, NPs, PAs, nurses, and other HCPs engaged in the care of patients with chronic myeloid leukemia (CML).

Learning Objectives

After completing this activity, the clinician should be able to:

  • Employ key data on tyrosine kinase inhibitors (TKIs) when treating and monitoring patients with relapsed or refractory CML
  • Select appropriate therapy for patients with CML refractory to 2nd generation agents
  • Integrate strategies to monitor and manage potential adverse effects, such as cardiotoxicity, that may result in cross-intolerance to TKIs in patients with CML

Activity Description

This Clinical Convergence™ activity addresses new developments in the treatment of relapsed/refractory CML with a focus on appropriate therapeutic decision making and monitoring in the second- and third-line setting. The program features a clinical case vignette to engage the learner and facilitate acquisition and integration of new skills and behaviors, as well as a patient encounter to provide unique perspectives on aspects of treatment selection, adherence, monitoring requirements, and adverse event management. A non-certified practice aid is included as a resource for provider-patient discussions on potential side effects.

Course Director

Jorge Cortes, MD
Director, Georgia Cancer Center
Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer
Augusta, GA

Faculty

Mahran Shoukier, MD
Hematology/Oncology Fellow
Section of Hematology/Oncology, Department of Medicine
Georgia Cancer Center at Augusta University
Augusta, GA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Jorge Cortes, MD, has affiliations with Novartis, Pfizer, Sun Pharmaceuticals, Takeda (Consultant and Grant Research Support).

Mahran Shoukier, MD, has no relevant financial relationship(s) with ineligible companies to disclose.

Patient
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planner, Sara Fagerlie, PhD, CHCP, has an affiliation with Adaptive Biotechnologies. All other RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.

No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

1.00 CME / CNE / CPE
Rush University Medical Center
Advances in CAR T-Cell Therapies: Optimizing Outcomes and Implementation in Hematologic Malignancies

Advances in CAR T-Cell Therapies: Optimizing Outcomes and Implementation in Hematologic Malignancies

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 9, 2021
Expires: June 8, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with hematologic malignancies.

Learning Objectives

After completing this program, participants should be able to:

  1. Assess the latest developments in CAR T-cell therapies for relapsed/refractory hematologic malignancies, including ongoing clinical trials.
  2. Identify adverse effects associated with CAR T-cell therapies in hematologic malignancies and describe effective approaches to appropriately manage these effects.
  3. Outline factors that interfere with the application of CAR T-cell therapies and formulate strategies to overcome these barriers.

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of hematologic malignancies. This educational activity will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the recent advances in CAR T-cell therapies for hematologic malignancies, the use of approved and investigational agents is anticipated to expand over the coming years. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the application of CAR T-cell therapy, ongoing clinical trials of CAR T-cell therapies, appropriate management of associated adverse effects, and best practices to overcome barriers associated with implementation of this treatment approach.

Faculty

Caron Jacobson, MD
Assistant Professor
Division of Medical Oncology
Department of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Conflict of Interest Policy/Disclosure Statement

Dr. Jacobson has consulted for:
Kite/Gilead, Novartis, BMS/Celgene, Nkarta, Lonza, bluebird bio, Precision Biosciences, Abbvie, Ipsen

Dr. Jacobson has research grants from
Pfizer, Kite Pharma

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from BMS, Gilead, Janssen Biotech, Inc., and Kite Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 9, 2021
Expires: June 8, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with hematologic malignancies.

Learning Objectives

After completing this program, participants should be able to:

  1. Assess the latest developments in CAR T-cell therapies for relapsed/refractory hematologic malignancies, including ongoing clinical trials.
  2. Identify adverse effects associated with CAR T-cell therapies in hematologic malignancies and describe effective approaches to appropriately manage these effects.
  3. Outline factors that interfere with the application of CAR T-cell therapies and formulate strategies to overcome these barriers.

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of hematologic malignancies. This educational activity will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the recent advances in CAR T-cell therapies for hematologic malignancies, the use of approved and investigational agents is anticipated to expand over the coming years. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the application of CAR T-cell therapy, ongoing clinical trials of CAR T-cell therapies, appropriate management of associated adverse effects, and best practices to overcome barriers associated with implementation of this treatment approach.

Faculty

Caron Jacobson, MD
Assistant Professor
Division of Medical Oncology
Department of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Conflict of Interest Policy/Disclosure Statement

Dr. Jacobson has consulted for:
Kite/Gilead, Novartis, BMS/Celgene, Nkarta, Lonza, bluebird bio, Precision Biosciences, Abbvie, Ipsen

Dr. Jacobson has research grants from
Pfizer, Kite Pharma

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from BMS, Gilead, Janssen Biotech, Inc., and Kite Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

0.25 CME / MOC
Postgraduate Institute for Medicine
Basal Cell Carcinoma: To Targeted Therapy and Beyond – High-Risk Basal Cell Carcinoma: Navigating Treatment and Complications

Basal Cell Carcinoma: To Targeted Therapy and Beyond – High-Risk Basal Cell Carcinoma: Navigating Treatment and Complications

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
ABIM MOC Points
Released: June 4, 2021
Expires: June 3, 2022
15 minutes to complete

Jointly Provided By

Jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the educational needs of dermatology and oncology physicians who diagnose and manage patients with basal cell carcinoma (BCC).

Learning Objective

After completing this activity, the clinician should be able to:

  • Assess current treatment options for the management of high-risk basal cell carcinoma (BCC)

Activity Description

Treatment decisions in basal cell carcinoma (BCC) are driven by estimated risk for recurrence. Although surgery is the treatment of choice for the majority of high-risk BCC, some large, deep, aggressive, or recurrent tumors can be classified as locally advanced and are best treated with systemic therapy. This Infographic activity provides detailed education on identifying high-risk BCC, the rationale for Mohs surgery, and appropriate use of local therapies. The role and place of systemic therapy is also defined, with an emphasis on the efficacy and limitations of Hedgehog pathway inhibitors (HPI) and the recent emergence of immunotherapy on the treatment landscape.

Statement of Educational Need

Current guideline-based recommendations for treating high-risk BCC, including lesions not amenable to surgery or radiation.

Faculty

Omid Hamid, MD
Chief, Translational Research and Immunotherapy
Director, Melanoma Center and Phase I Immuno-Oncology Program
The Angeles Clinic and Research Institute
Los Angeles, CA

Disclosures:
Speakers Bureau: BMS, Novartis, Pfizer, Sanofi/Regeneron
Consulting Fees: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Genentech, GSK, Immunocore, Idera, Incyste, Jannsen, Merck, Nextcure, Novartis, Pfizer, Sanofi/Regeneron, SeaGen, Tempus, Zelluna

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The RMEI Medical Education planners and others have nothing to disclose. The patient in this activity has nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact PIM at inquiries@pimed.com.

Users must:

  • Read the learning objective and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation form and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

Please contact Nicole Neely at nneely@rmei.com. For accreditation questions, please contact PIM at inquiries@pimed.com.

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
ABIM MOC Points
Released: June 4, 2021
Expires: June 3, 2022
15 minutes to complete

Jointly Provided By

Jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the educational needs of dermatology and oncology physicians who diagnose and manage patients with basal cell carcinoma (BCC).

Learning Objective

After completing this activity, the clinician should be able to:

  • Assess current treatment options for the management of high-risk basal cell carcinoma (BCC)

Activity Description

Treatment decisions in basal cell carcinoma (BCC) are driven by estimated risk for recurrence. Although surgery is the treatment of choice for the majority of high-risk BCC, some large, deep, aggressive, or recurrent tumors can be classified as locally advanced and are best treated with systemic therapy. This Infographic activity provides detailed education on identifying high-risk BCC, the rationale for Mohs surgery, and appropriate use of local therapies. The role and place of systemic therapy is also defined, with an emphasis on the efficacy and limitations of Hedgehog pathway inhibitors (HPI) and the recent emergence of immunotherapy on the treatment landscape.

Statement of Educational Need

Current guideline-based recommendations for treating high-risk BCC, including lesions not amenable to surgery or radiation.

Faculty

Omid Hamid, MD
Chief, Translational Research and Immunotherapy
Director, Melanoma Center and Phase I Immuno-Oncology Program
The Angeles Clinic and Research Institute
Los Angeles, CA

Disclosures:
Speakers Bureau: BMS, Novartis, Pfizer, Sanofi/Regeneron
Consulting Fees: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Genentech, GSK, Immunocore, Idera, Incyste, Jannsen, Merck, Nextcure, Novartis, Pfizer, Sanofi/Regeneron, SeaGen, Tempus, Zelluna

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The RMEI Medical Education planners and others have nothing to disclose. The patient in this activity has nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact PIM at inquiries@pimed.com.

Users must:

  • Read the learning objective and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation form and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

Please contact Nicole Neely at nneely@rmei.com. For accreditation questions, please contact PIM at inquiries@pimed.com.

1.00 CME / CNE / CPE
Rush University Medical Center
Precision Medicine to Improve Lung Cancer Outcomes: Recent Therapeutic Advances and Emerging Agents

Precision Medicine to Improve Lung Cancer Outcomes: Recent Therapeutic Advances and Emerging Agents

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: May 14, 2021
Expires: May 13, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with lung cancer.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  1. Describe the common molecular alterations and recommended biomarker testing to inform clinical decision-making for patients with lung cancer.
  2. Assess the latest clinical evidence regarding the safety and efficacy of recently approved therapies for lung cancer.
  3. Formulate informed treatment plans for patients with lung cancer, taking into consideration clinical data regarding combination therapies and sequencing approaches.
  4. Review the mechanism of action and available clinical data for investigational agents under development and their potential role in the context of existing lung cancer treatment paradigms.

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of lung cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

Recent advances in the understanding of molecular alterations associated with treatment outcomes in patients with lung cancer have advanced personalized therapy decisions. However, despite guidelines recommending biomarker testing, a substantial fraction of patients with lung cancer do not receive these tests. Clinicians are challenged to remain abreast of the most recent recommendations regarding biomarker testing, interpretation, and associated treatment options.

Numerous options, including both targeted agents and immunotherapies, have been approved for the treatment of lung cancer in recent years, and data continue to emerge regarding their efficacy, safety, and optimal combinations and sequencing. Given the recent rapid pace of advances, clinicians are challenged to remain aware of the latest clinical outcomes.

In addition to recently approved agents, a wide variety of promising investigational agents targeting common molecular alterations in lung cancer are currently under development. However, clinicians may not be fully aware of the clinical data regarding these emerging therapies or how to place these agents within current lung cancer treatment paradigms.

Faculty

Millie Das, MD
Clinical Associate Professor, Stanford University
Chief, Oncology, VA Palo Alto Health Care System
Palo Alto, CA

Conflict of Interest Policy/Disclosure Statement

Dr. Das has consulted for:
Jazz Pharmaceuticals (ended in July 2020)

Dr. Das has research grants from:
Novartis, Verily, Abbvie, United Therapeutics, Celgene

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Novartis.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: May 14, 2021
Expires: May 13, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with lung cancer.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  1. Describe the common molecular alterations and recommended biomarker testing to inform clinical decision-making for patients with lung cancer.
  2. Assess the latest clinical evidence regarding the safety and efficacy of recently approved therapies for lung cancer.
  3. Formulate informed treatment plans for patients with lung cancer, taking into consideration clinical data regarding combination therapies and sequencing approaches.
  4. Review the mechanism of action and available clinical data for investigational agents under development and their potential role in the context of existing lung cancer treatment paradigms.

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of lung cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

Recent advances in the understanding of molecular alterations associated with treatment outcomes in patients with lung cancer have advanced personalized therapy decisions. However, despite guidelines recommending biomarker testing, a substantial fraction of patients with lung cancer do not receive these tests. Clinicians are challenged to remain abreast of the most recent recommendations regarding biomarker testing, interpretation, and associated treatment options.

Numerous options, including both targeted agents and immunotherapies, have been approved for the treatment of lung cancer in recent years, and data continue to emerge regarding their efficacy, safety, and optimal combinations and sequencing. Given the recent rapid pace of advances, clinicians are challenged to remain aware of the latest clinical outcomes.

In addition to recently approved agents, a wide variety of promising investigational agents targeting common molecular alterations in lung cancer are currently under development. However, clinicians may not be fully aware of the clinical data regarding these emerging therapies or how to place these agents within current lung cancer treatment paradigms.

Faculty

Millie Das, MD
Clinical Associate Professor, Stanford University
Chief, Oncology, VA Palo Alto Health Care System
Palo Alto, CA

Conflict of Interest Policy/Disclosure Statement

Dr. Das has consulted for:
Jazz Pharmaceuticals (ended in July 2020)

Dr. Das has research grants from:
Novartis, Verily, Abbvie, United Therapeutics, Celgene

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Novartis.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

0.50 CME / MOC
AKH Inc., Advancing Knowledge in Healthcare
Nonmelanoma Skin Cancers: Real-World Perspectives on Individualizing Care—Real-World Perspectives on Shared Decision Making in Advanced NMSC

Nonmelanoma Skin Cancers: Real-World Perspectives on Individualizing Care—Real-World Perspectives on Shared Decision Making in Advanced NMSC

Start

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
ABIM MOC point(s)
Released: May 13, 2021
Expires: May 12, 2022
30 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

This educational activity is designed to meet the needs of medical oncology physicians, dermatology physicians, and other clinicians involved in the management of cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Assess safety and efficacy data for checkpoint inhibitors in advanced cutaneous squamous cell carcinoma (CSCC)
  • Outline approaches in shared decision making to improve outcomes and quality of life in patients with advanced CSCC
  • Evaluate current and emerging options for systemic treatment in advanced basal cell carcinoma (BCC)
  • Employ shared decision making, quality of life assessment and management, and collaborative care to improve outcomes in patients with advanced BCC

Activity Description

This activity uniquely features 2 experts in the treatment of advanced nonmelanoma skin cancers (NMSC) and also 2 patients—one with CSCC, and the other with BCC—in an interactive panel discussion highlighting the role of shared decision making and its optimal integration into clinical practice.

Statement of Educational Need

Clinicians need exposure to the latest advances in the management of advanced NMSC, and insight into optimal integration of key data with patient perspectives in the shared decision-making process.

Faculty

Michael R. Migden, MD
Professor, Department of Dermatology, Division of Internal Medicine
University of Texas MD Anderson Cancer Center
Houston, TX


Ahmad Tarhini, MD, PhD
Senior Member, Cutaneous Oncology and Immunology
Director, Cutaneous Clinical and Translational Research
H. Lee Moffitt Cancer Center and Research Institute
Professor, Oncologic Sciences
University of South Florida Morsani College of Medicine
Tampa, FL

Disclosure Declaration

It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose. RMEI Medical Education, LLC planners and reviewers have no relevant financial relationships to disclose.

Michael R. Migden, MD, has affiliations with Regeneron, Sanofi, Sun Pharmaceuticals (Consultant).

Ahmad Tarhini, MD, PhD, has affiliations with Bristol Myers Squibb, Eisai, Genentech-Roche, Merck, Novartis, Partner Therapeutics, Sanofi-Genzyme/Regeneron (Consultant); Clinigen, Genentech-Roche, OncoSec (Contracted Research).

Brian Christensen – Patient, has no financial relationships to disclose.
Tom Hunter – Patient, has no financial relationships to disclose.

RMEI Disclosures
Elizabeth Johnson, MA, RMEI Reviewer, has disclosed no financial relationships.
Laurie Orloski, PharmD, RPh, RMEI Medical Writer, has disclosed no financial relationships.
Sharon Powell, RMEI Senior Medical Editor, has disclosed no financial relationships.
Yael Waknine, RMEI Medical Director, has disclosed no financial relationships.

AKH Disclosures
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer, has disclosed no financial relationships.
Patricia Brignoni, AKH Director of Operations/Reviewer, has disclosed no financial relationships.

AKH Inc. and RMEI planners and reviewers disclosed no financial relationships.
All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) and 0 patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity.

Criteria for Success
Statements of credit will be awarded based on the participant’s attendance, participation in the pre-/post-test, and submission of the activity evaluation form. A statement of credit will be available upon completion of an evaluation/claimed credit form.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
ABIM MOC point(s)
Released: May 13, 2021
Expires: May 12, 2022
30 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

This educational activity is designed to meet the needs of medical oncology physicians, dermatology physicians, and other clinicians involved in the management of cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Assess safety and efficacy data for checkpoint inhibitors in advanced cutaneous squamous cell carcinoma (CSCC)
  • Outline approaches in shared decision making to improve outcomes and quality of life in patients with advanced CSCC
  • Evaluate current and emerging options for systemic treatment in advanced basal cell carcinoma (BCC)
  • Employ shared decision making, quality of life assessment and management, and collaborative care to improve outcomes in patients with advanced BCC

Activity Description

This activity uniquely features 2 experts in the treatment of advanced nonmelanoma skin cancers (NMSC) and also 2 patients—one with CSCC, and the other with BCC—in an interactive panel discussion highlighting the role of shared decision making and its optimal integration into clinical practice.

Statement of Educational Need

Clinicians need exposure to the latest advances in the management of advanced NMSC, and insight into optimal integration of key data with patient perspectives in the shared decision-making process.

Faculty

Michael R. Migden, MD
Professor, Department of Dermatology, Division of Internal Medicine
University of Texas MD Anderson Cancer Center
Houston, TX


Ahmad Tarhini, MD, PhD
Senior Member, Cutaneous Oncology and Immunology
Director, Cutaneous Clinical and Translational Research
H. Lee Moffitt Cancer Center and Research Institute
Professor, Oncologic Sciences
University of South Florida Morsani College of Medicine
Tampa, FL

Disclosure Declaration

It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose. RMEI Medical Education, LLC planners and reviewers have no relevant financial relationships to disclose.

Michael R. Migden, MD, has affiliations with Regeneron, Sanofi, Sun Pharmaceuticals (Consultant).

Ahmad Tarhini, MD, PhD, has affiliations with Bristol Myers Squibb, Eisai, Genentech-Roche, Merck, Novartis, Partner Therapeutics, Sanofi-Genzyme/Regeneron (Consultant); Clinigen, Genentech-Roche, OncoSec (Contracted Research).

Brian Christensen – Patient, has no financial relationships to disclose.
Tom Hunter – Patient, has no financial relationships to disclose.

RMEI Disclosures
Elizabeth Johnson, MA, RMEI Reviewer, has disclosed no financial relationships.
Laurie Orloski, PharmD, RPh, RMEI Medical Writer, has disclosed no financial relationships.
Sharon Powell, RMEI Senior Medical Editor, has disclosed no financial relationships.
Yael Waknine, RMEI Medical Director, has disclosed no financial relationships.

AKH Disclosures
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer, has disclosed no financial relationships.
Patricia Brignoni, AKH Director of Operations/Reviewer, has disclosed no financial relationships.

AKH Inc. and RMEI planners and reviewers disclosed no financial relationships.
All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) and 0 patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity.

Criteria for Success
Statements of credit will be awarded based on the participant’s attendance, participation in the pre-/post-test, and submission of the activity evaluation form. A statement of credit will be available upon completion of an evaluation/claimed credit form.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

0.50 CME / MOC
AKH Inc., Advancing Knowledge in Healthcare
Nonmelanoma Skin Cancers: Real-World Perspectives on Individualizing Care—Case Challenges in NMSC Management

Nonmelanoma Skin Cancers: Real-World Perspectives on Individualizing Care—Case Challenges in NMSC Management

Start

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
ABIM MOC point(s)
Released: May 13, 2021
Expires: May 12, 2022
30 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

This educational activity is designed to meet the needs of medical oncology physicians, dermatology physicians, and other clinicians involved in the management of cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Assess safety and efficacy data for checkpoint inhibitors in advanced cutaneous squamous cell carcinoma (CSCC)
  • Outline approaches in shared decision making to improve outcomes and quality of life in patients with advanced CSCC
  • Evaluate current and emerging options for systemic treatment in advanced basal cell carcinoma (BCC)
  • Employ shared decision making, quality of life assessment and management, and collaborative care to improve outcomes in patients with advanced BCC

Activity Description

In this activity, experts in the treatment of advanced nonmelanoma skin cancers (NMSC) will review 2 case challenges—one in CSCC and the other in BCC—that highlight the latest data and offer learners a unique opportunity to rethink key clinical decisions for optimal patient outcomes.

Statement of Educational Need

Clinicians need exposure to the latest advances in the management of advanced NMSC, and insight into optimal integration of key data with patient perspectives in the shared decision-making process.

Faculty

Michael R. Migden, MD
Professor, Department of Dermatology, Division of Internal Medicine
University of Texas MD Anderson Cancer Center
Houston, TX


Ahmad Tarhini, MD, PhD
Senior Member, Cutaneous Oncology and Immunology
Director, Cutaneous Clinical and Translational Research
H. Lee Moffitt Cancer Center and Research Institute
Professor, Oncologic Sciences
University of South Florida Morsani College of Medicine
Tampa, FL

Disclosure Declaration

It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose. RMEI Medical Education, LLC planners and reviewers have no relevant financial relationships to disclose.

Michael R. Migden, MD, has affiliations with Regeneron, Sanofi, Sun Pharmaceuticals (Consultant).

Ahmad Tarhini, MD, PhD, has affiliations with Bristol Myers Squibb, Eisai, Genentech-Roche, Merck, Novartis, Partner Therapeutics, Sanofi-Genzyme/Regeneron (Consultant); Clinigen, Genentech-Roche, OncoSec (Contracted Research).

Brian Christensen – Patient, has no financial relationships to disclose.
Tom Hunter – Patient, has no financial relationships to disclose.

RMEI Disclosures
Elizabeth Johnson, MA, RMEI Reviewer, has disclosed no financial relationships.
Laurie Orloski, PharmD, RPh, RMEI Medical Writer, has disclosed no financial relationships.
Sharon Powell, RMEI Senior Medical Editor, has disclosed no financial relationships.
Yael Waknine, RMEI Medical Director, has disclosed no financial relationships.

AKH Disclosures
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer, has disclosed no financial relationships.
Patricia Brignoni, AKH Director of Operations/Reviewer, has disclosed no financial relationships.

AKH Inc. and RMEI planners and reviewers disclosed no financial relationships.
All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) and 0 patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity.

Criteria for Success
Statements of credit will be awarded based on the participant’s attendance, participation in the pre-/post-test, and submission of the activity evaluation form. A statement of credit will be available upon completion of an evaluation/claimed credit form.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
ABIM MOC point(s)
Released: May 13, 2021
Expires: May 12, 2022
30 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

This educational activity is designed to meet the needs of medical oncology physicians, dermatology physicians, and other clinicians involved in the management of cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Assess safety and efficacy data for checkpoint inhibitors in advanced cutaneous squamous cell carcinoma (CSCC)
  • Outline approaches in shared decision making to improve outcomes and quality of life in patients with advanced CSCC
  • Evaluate current and emerging options for systemic treatment in advanced basal cell carcinoma (BCC)
  • Employ shared decision making, quality of life assessment and management, and collaborative care to improve outcomes in patients with advanced BCC

Activity Description

In this activity, experts in the treatment of advanced nonmelanoma skin cancers (NMSC) will review 2 case challenges—one in CSCC and the other in BCC—that highlight the latest data and offer learners a unique opportunity to rethink key clinical decisions for optimal patient outcomes.

Statement of Educational Need

Clinicians need exposure to the latest advances in the management of advanced NMSC, and insight into optimal integration of key data with patient perspectives in the shared decision-making process.

Faculty

Michael R. Migden, MD
Professor, Department of Dermatology, Division of Internal Medicine
University of Texas MD Anderson Cancer Center
Houston, TX


Ahmad Tarhini, MD, PhD
Senior Member, Cutaneous Oncology and Immunology
Director, Cutaneous Clinical and Translational Research
H. Lee Moffitt Cancer Center and Research Institute
Professor, Oncologic Sciences
University of South Florida Morsani College of Medicine
Tampa, FL

Disclosure Declaration

It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose. RMEI Medical Education, LLC planners and reviewers have no relevant financial relationships to disclose.

Michael R. Migden, MD, has affiliations with Regeneron, Sanofi, Sun Pharmaceuticals (Consultant).

Ahmad Tarhini, MD, PhD, has affiliations with Bristol Myers Squibb, Eisai, Genentech-Roche, Merck, Novartis, Partner Therapeutics, Sanofi-Genzyme/Regeneron (Consultant); Clinigen, Genentech-Roche, OncoSec (Contracted Research).

Brian Christensen – Patient, has no financial relationships to disclose.
Tom Hunter – Patient, has no financial relationships to disclose.

RMEI Disclosures
Elizabeth Johnson, MA, RMEI Reviewer, has disclosed no financial relationships.
Laurie Orloski, PharmD, RPh, RMEI Medical Writer, has disclosed no financial relationships.
Sharon Powell, RMEI Senior Medical Editor, has disclosed no financial relationships.
Yael Waknine, RMEI Medical Director, has disclosed no financial relationships.

AKH Disclosures
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer, has disclosed no financial relationships.
Patricia Brignoni, AKH Director of Operations/Reviewer, has disclosed no financial relationships.

AKH Inc. and RMEI planners and reviewers disclosed no financial relationships.
All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) and 0 patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity.

Criteria for Success
Statements of credit will be awarded based on the participant’s attendance, participation in the pre-/post-test, and submission of the activity evaluation form. A statement of credit will be available upon completion of an evaluation/claimed credit form.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

1.00 CME / MOC
Global Education Group
The HER Family: A Pan Tumor Approach

The HER Family: A Pan Tumor Approach

Start

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)™/
ABIM MOC Point(s)
Released: May 12, 2021
Expires: May 11, 2022
60 minutes to complete

Accredited By

This activity is provided by Global Education Group. Produced in collaboration with RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the educational needs of medical and surgical oncologists, pathologists, oncology NPs and PAs, and pulmonologists who diagnose and manage patients with breast cancer, non-small cell lung cancer (NSCLC), and/or gastric cancer.

Learning Objectives

Upon completion of this activity, the clinician should be able to:

  • Employ available data on newly approved and investigational HER2- and HER3-directed therapies for advanced breast cancer 
  • Assess the therapeutic potential role and place of HER2- and HER3-targeted agents in non-small cell lung cancer (NSCLC) 
  • Apply current evidence for new frontline combinations in HER2+ advanced gastric cancer, as well as new and emerging options for refractory disease 

Activity Description

During this Clinical Forum℠ activity, 3 nationally recognized experts in the management of solid tumors discuss approved and emerging therapeutic approaches targeting HER2 or HER3 in patients with breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer.

Statement of Educational Need

Clinical research seeks to expand the treatment armamentarium for solid tumors by investigating new or emerging HER2-targeted therapies in breast, lung, and gastric cancer; targeting HER3 and other escape mechanisms are also of interest. Given the rapidly evolving landscape of HER2-targeted therapies and the emerging role of HER3, clinicians require clear knowledge of the latest advances in order to deliver optimal cancer care.

Faculty

Sara M. Tolaney, MD, MPH
Associate Director, Susan F. Smith Center for Women’s Cancer
Director, Clinical Trials, Breast Oncology Center
Senior Physician
Dana-Farber Cancer Institute
Associate Professor, Medicine
Harvard Medical School
Boston, MA


Daniel Catenacci, MD
Associate Professor, Department of Medicine, Section of Hematology & Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research, Comprehensive Cancer Center
The University of Chicago Medical Center & Biological Sciences
Chicago, IL


Liza C. Villaruz, MD
Associate Professor, Medicine
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, PA 

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Sara M. Tolaney, MD, MPH
Consultant: AstraZeneca, Athenex, Bristol-Myers Squibb, Certara, CytomX, Daiichi Sankyo, Eisai, Eli Lilly, G1 Therapeutics, Genentech/Roche, Immunomedics/Gilead, Kyowa Kirin Pharmaceutics, Merck, Mersana Therapeutics, Nanostring, Nektar, Novartis, Odonate, OncoPep, OncoSec, Pfizer, Puma, Samsung Bioepsis, Sanofi, SeaGen.
Contracted Research: AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Eli Lilly, Exelixis, Genentech/Roche, Immunomedics/Gilead, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, SeaGen.
 
Daniel Catenacci, MD
Consultant: Amgen, Archer & Natera, Arcus, Astellas, Basilea, BMS, Daiichi Sankyo, Eli Lilly, Five Prime, Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Merck, Pieris, QED, Seattle Genetics, Taiho, Tempus, Zymeworks.
Honoraria: Amgen, Archer & Natera, Arcus, Astellas, Basilea, BMS, Daiichi Sankyo, Eli Lilly, Five Prime, Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Merck, Pieris, QED, Seattle Genetics, Taiho, Tempus, Zymeworks.
Speaker’s Bureau: Daiichi Sankyo, Eli Lilly, Genentech/Roche, Guardant Health, Merck, Tempus.  

Liza C. Villaruz, MD, has nothing to disclose.  

The planners and managers have the following relevant financial relationships with ineligible companies:
  
Lindsay Borvansky has nothing to disclose. 
Andrea Funk has nothing to disclose. 
Liddy Knight has nothing to disclose. 
Ashley Cann has nothing to disclose. 
Agnes Yang has nothing to disclose. 
Sharon Powell has nothing to disclose. 
Elizabeth Johnson has nothing to disclose.  

Accreditation Statement

Physician Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on May 12, 2021 and is valid for one year. Requests for credit must be made no later than May 11, 2022.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) does not recommend the use of any agent outside of the labeled indications.     

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)™/
ABIM MOC Point(s)
Released: May 12, 2021
Expires: May 11, 2022
60 minutes to complete

Accredited By

This activity is provided by Global Education Group. Produced in collaboration with RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the educational needs of medical and surgical oncologists, pathologists, oncology NPs and PAs, and pulmonologists who diagnose and manage patients with breast cancer, non-small cell lung cancer (NSCLC), and/or gastric cancer.

Learning Objectives

Upon completion of this activity, the clinician should be able to:

  • Employ available data on newly approved and investigational HER2- and HER3-directed therapies for advanced breast cancer 
  • Assess the therapeutic potential role and place of HER2- and HER3-targeted agents in non-small cell lung cancer (NSCLC) 
  • Apply current evidence for new frontline combinations in HER2+ advanced gastric cancer, as well as new and emerging options for refractory disease 

Activity Description

During this Clinical Forum℠ activity, 3 nationally recognized experts in the management of solid tumors discuss approved and emerging therapeutic approaches targeting HER2 or HER3 in patients with breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer.

Statement of Educational Need

Clinical research seeks to expand the treatment armamentarium for solid tumors by investigating new or emerging HER2-targeted therapies in breast, lung, and gastric cancer; targeting HER3 and other escape mechanisms are also of interest. Given the rapidly evolving landscape of HER2-targeted therapies and the emerging role of HER3, clinicians require clear knowledge of the latest advances in order to deliver optimal cancer care.

Faculty

Sara M. Tolaney, MD, MPH
Associate Director, Susan F. Smith Center for Women’s Cancer
Director, Clinical Trials, Breast Oncology Center
Senior Physician
Dana-Farber Cancer Institute
Associate Professor, Medicine
Harvard Medical School
Boston, MA


Daniel Catenacci, MD
Associate Professor, Department of Medicine, Section of Hematology & Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research, Comprehensive Cancer Center
The University of Chicago Medical Center & Biological Sciences
Chicago, IL


Liza C. Villaruz, MD
Associate Professor, Medicine
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, PA 

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Sara M. Tolaney, MD, MPH
Consultant: AstraZeneca, Athenex, Bristol-Myers Squibb, Certara, CytomX, Daiichi Sankyo, Eisai, Eli Lilly, G1 Therapeutics, Genentech/Roche, Immunomedics/Gilead, Kyowa Kirin Pharmaceutics, Merck, Mersana Therapeutics, Nanostring, Nektar, Novartis, Odonate, OncoPep, OncoSec, Pfizer, Puma, Samsung Bioepsis, Sanofi, SeaGen.
Contracted Research: AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Eli Lilly, Exelixis, Genentech/Roche, Immunomedics/Gilead, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, SeaGen.
 
Daniel Catenacci, MD
Consultant: Amgen, Archer & Natera, Arcus, Astellas, Basilea, BMS, Daiichi Sankyo, Eli Lilly, Five Prime, Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Merck, Pieris, QED, Seattle Genetics, Taiho, Tempus, Zymeworks.
Honoraria: Amgen, Archer & Natera, Arcus, Astellas, Basilea, BMS, Daiichi Sankyo, Eli Lilly, Five Prime, Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Merck, Pieris, QED, Seattle Genetics, Taiho, Tempus, Zymeworks.
Speaker’s Bureau: Daiichi Sankyo, Eli Lilly, Genentech/Roche, Guardant Health, Merck, Tempus.  

Liza C. Villaruz, MD, has nothing to disclose.  

The planners and managers have the following relevant financial relationships with ineligible companies:
  
Lindsay Borvansky has nothing to disclose. 
Andrea Funk has nothing to disclose. 
Liddy Knight has nothing to disclose. 
Ashley Cann has nothing to disclose. 
Agnes Yang has nothing to disclose. 
Sharon Powell has nothing to disclose. 
Elizabeth Johnson has nothing to disclose.  

Accreditation Statement

Physician Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on May 12, 2021 and is valid for one year. Requests for credit must be made no later than May 11, 2022.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) does not recommend the use of any agent outside of the labeled indications.     

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com. 

Pages